The work, led by Dr. Rui Su’s group at City of Hope, demonstrates that targeting the METTL1-mediated m7G pathway selectively disrupts leukemic stem cell function while largely sparing normal hematopoietic stem cells, highlighting a promising new therapeutic strategy for AML.
Key Discovery 1. m7G Modification Sustains Leukemia Stem Cell Translation
m7G on tRNAs has long been regarded as a structural modification that stabilizes these molecules. This study reveals an unexpected function: m7G acts as a switch for selective protein translation.
The authors showed that:
• Leukemia stem cells (LSCs) depend strongly on METTL1, the methyltransferase that deposits m7G on tRNAs.
• tRNA-Phe(GAA) is among the most abundant and METTL1-dependent tRNAs in LSCs.
• METTL1 loss sharply reduces m7G-modified tRNA-Phe(GAA), blocking translation of phenylalanine-codon-enriched transcripts.
• Ribosome stalling then activates the No-Go Decay (NGD) pathway, degrading incompletely translated mRNAs.
Together these results show that tRNA m7G modification directly governs translation efficiency and transcript stability in leukemia stem cells.
Key Discovery 2. Disrupting m7G Prevents Leukemia Stem Cell Homing
Perhaps the most striking finding is that tRNA m7G modification controls whether leukemia stem cells can home to the bone marrow.
The study identified HCK, a Src-family kinase in CXCR4-mediated signaling, as a critical downstream target. After METTL1 inhibition:
• HCK translation is markedly reduced.
• CXCR4 signaling becomes impaired.
• LSCs lose their ability to migrate toward CXCL12-rich bone marrow niches.
• Without microenvironmental protection, LSC self-renewal declines and leukemic progression is suppressed.
These results establish m7G-dependent translation as an essential regulator of leukemia stem cell fitness and niche adaptation.
Key Discovery 3. First-in-Class METTL1 Inhibitor Targets the m7G Axis
Building on these mechanistic insights, the investigators identified M1i (NSC137443) through high-throughput screening.
M1i directly inhibits METTL1, leading to:
• Reduced intracellular m7G levels.
• Selective depletion of leukemia stem cells.
• Suppression of AML progression in multiple mouse and patient-derived xenograft (PDX) models.
• Minimal effects on normal hematopoietic stem cells.
These findings position the METTL1-m7G pathway as an attractive therapeutic target for AML.
Research Spotlight: Why Analyze tRNA m7G Modification?
This study illustrates how tRNA modifications can selectively regulate protein synthesis, ribosome dynamics, stem cell biology, and disease progression. Comprehensive m7G profiling is increasingly important for understanding cancer stem cell biology, translational regulation, RNA modification-mediated gene expression, and precision oncology and drug discovery.
Accelerate Your m7G Research with Arraystar TRAC-seq
Arraystar TRAC-seq (tRNA Reduction and Alkylation Coupled Sequencing) enables transcriptome-wide, single-nucleotide profiling of tRNA m7G modifications, providing a powerful solution for investigating METTL1-dependent translational regulation.
Key Advantages
• Transcriptome-wide profiling of tRNA m7G modifications.
• Single-nucleotide resolution.
• Quantitative comparison across biological conditions.
• Publication-ready bioinformatics analysis.